≡

Multiplex Assay Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay)

MAPKK1; MEK1; MKK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; ERK activator kinase 1

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 94-103 99
EDTA plasma(n=5) 95-102 98
heparin plasma(n=5) 80-98 94

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 99-105% 95-105% 96-103% 79-94%
EDTA plasma(n=5) 91-105% 89-103% 84-102% 85-103%
heparin plasma(n=5) 80-91% 78-101% 95-103% 96-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:MAP2K1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Graefe's Archive for Clinical and Experimental Ophthalmology Role of RhoA/MERK1/ERK1/2/iNOS signaling in ocular ischemic syndrome pubmed:27538909
PLOS ONE Identification of Biomarkers of Impaired Sensory Profiles among Autistic Patients. pubmed:27824861
Cancers Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075
Cancers (Basel) BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPD559Hu01 Recombinant Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) Positive Control; Immunogen; SDS-PAGE; WB.
PAD559Hu01 Polyclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) WB; IHC; ICC; IP.
MAD559Hu21 Monoclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) WB; IHC; ICC; IP.
SED559Hu ELISA Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMD559Hu Multiplex Assay Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.